Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the selinexor maintenance study in advanced or recurrent endometrial cancer is displayed, with its study design, eligibility criteria, measures, and locations. The record indicates the study is active but no longer recruiting.SummaryDifference100%

- Check15 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study content and preventing access to the ClinicalTrials.gov record.SummaryDifference0.5%

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.